Reducing Residual Vascular Risk Through combination Therapy with Fenofibrate and Alpha-Lipoic Acid in Patients with Ischemic Heart Disease and Type 2 Diabetes Mellitus

dc.contributor.authorZhuravlyova, Larysa
dc.contributor.authorLopina, Nataliia
dc.date.accessioned2012-11-22T08:31:59Z
dc.date.available2012-11-22T08:31:59Z
dc.date.issued2012
dc.description.abstractTo investigate effects of combination therapy with fenofibrate and α-lipoic acid on atherogenic dyslipidemia, which determines the residual vascular risk and endothelial dysfunction, levels of proinflammatory mediators in patients with ischemic heart disease and type 2 diabetes mellitus.uk_UK
dc.identifier.citationZhuravlyova L. Reducing Residual Vascular Risk Through combination Therapy with Fenofibrate and Alpha-Lipoic Acid in Patients with Ischemic Heart Disease and Type 2 Diabetes Mellitus : Abstracts from 15th International & 14th European Congress of Endocrinology, Florence, Italy, 5–9 May, 2012 / L. Zhuravlova, N. Lopina // Endocrine Abstracts. – 2012. – Vol. 29. – P. 713.uk_UK
dc.identifier.urihttps://repo.knmu.edu.ua/handle/123456789/1684
dc.language.isoenuk_UK
dc.subjectresidual vascular riskuk_UK
dc.subjectfenofibrateuk_UK
dc.subjectalpha-lipoic aciduk_UK
dc.subjectischemic heart diseaseuk_UK
dc.subjecttype 2 diabetes mellitusuk_UK
dc.titleReducing Residual Vascular Risk Through combination Therapy with Fenofibrate and Alpha-Lipoic Acid in Patients with Ischemic Heart Disease and Type 2 Diabetes Mellitusuk_UK
dc.typeArticleuk_UK

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Reducing.pdf
Size:
77.18 KB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
6.52 KB
Format:
Item-specific license agreed upon to submission
Description: